Media Advisory: Public Session of the Cancer Drug Development Roundtable at Ohio State

April 25, 2011

WHAT: Public Session of the Cancer Drug Development Roundtable at Ohio State

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and Friends of Cancer Research (Friends) are convening a high-level group of stakeholders to discuss current obstacles halting co-development of two or more experimental drugs for the treatment of cancer.

In December 2010, the U.S. Food and Drug Administration (FDA) released a Guidance Document addressing the protocol researchers should follow when deciding if co-developing drugs is appropriate. However, barriers found outside of clinics and labs, such as business, legal, liability and intellectual property issues were not examined in detail.

The objective of the Cancer Drug Development Roundtable is to develop a set of recommendations for the FDA to be revealed later this year, addressing industry hurdles currently halting co-development, with the ultimate goal of easing the process and bringing revolutionary cancer treatments to patients faster and with more efficiency.

Prior to the closed working session occurring later in the day, Roundtable participants will hold an open public session for researchers, advocates, patients and media that would like to learn more about the issue and ask questions. Panel participants include:

  • Michael Caligiuri, M.D. - Director of The Ohio State Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute
  • Jim Doroshow, M.D. - Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute
  • Eric Rubin, M.D. - Vice President, Oncology Clinical Research, Merck
  • Ellen Sigal, Ph.D. - Chair and Founder, Friends of Cancer Research
  • Janet Woodcock, M.D. - Director, Center for Drug Evaluation and Research, FDA

WHERE: The Ohio State University, Biomedical Research Tower, Room 115, 460 W. 12th Avenue, Columbus, OH 43210

For those unable to attend in person, the Public Session will also be made available via Webcast and teleconference (Please RSVP to lbryan@spectrumscience.com for dial-in information and link).

WHEN: Wednesday, May 4, 2011

10:00 – 11:00 a.m.

WHO: Hosted by Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and Friends of Cancer Research (Friends)

# # #

Eileen Scahill
Medical Center Public Affairs and Media Relations
614-293-3737
Eileen.Scahill@osumc.edu

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Prostate Cancer Androgen Receptor Activates a Different Gene Set When Bound to Antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by...

Read More

Individualizing Treatments for Multiple Myeloma

This week on Toward a Cancer-Free World, Dr. Craig Hofmeister shares how using an actual virus to help treat certain blood cancer patients may just get us even closer to a cancer-free world.

Read More

Generating New Hope Through Pelotonia-Funded Research

Pelotonia funds support cancer drug development projects at Ohio State. Here’s a brief look at a basic-science study of a targeted agent that may improve cancer-killing virus therapy, and two clinical...

Read More